Tempus Technology

Bringing data and AI to healthcare

We’re building innovative tech solutions oriented around clinical care and research products—and the virtuous cycle between them.

Hub
  • for Providers

Hub

A desktop and mobile platform for ordering, managing, and receiving Tempus tests and patient results.

  • Secure access to patient information

    Review test results and build custom cohorts.

  • Easy order management

    Order tests, check order status, and review patient results.

  • Access to smart reporting

    View clinical reports to determine treatment options based on MSK OncoKB, NCCN Guidelines®, and clinical/molecular data.

Learn more
One
  • For Providers

One

AI-enabled clinical assistant that provides access to patient insights directly at your fingertips.

  • Retrieve patient information

    Quickly access patient information, like report status, results on actionable biomarkers, and MSI/TMB status.

  • Filter patients by alterations, genes, or diagnoses

    View relevant cohorts of your patients for additional insights that may support you in patient treatment decisions.

  • Identify relevant, up-to-date clinical trials

    Discover the latest clinical trials based on specific patient enrollment criteria so your patients can receive care quickly.

Learn more
Now
  • For Providers

Now

Suite of applications that live inside EHRs.

  • Seamless EHR ordering and result delivery

    Place orders and receive results, directly in your EHR.

  • Unlock structured genomic data

    Discrete genomic data can power your EHR’s decision-making, advanced analytics, and clinical research.

  • Refresh therapies and clinical trials

    Refresh therapies and clinical trials available for your patients based on previous test results – all inside your EHR.

Learn more
Lens
  • for life sciences

Lens

A central platform for partners to interact with Tempus data and services.

  • Define cohorts of interest

    Apply Inclusion and Exclusion criteria to find patients of interest with Lens Cohort Definition.
  • Refine and visualize

    Gain insight from quick no-code analyses with Lens Analytical Apps.

  • Analyze to uncover critical insights

    Leverage RWD in a flexible computational environment with Lens Workspaces, using R and Jupyter Notebooks.

Learn more
Pixel
  • for Providers

Pixel

AI-enabled insights from medical images.

  • Automated quantification

    Segments and measures lesions of interest, providing accurate contours and long-axis and short-axis measurements.

  • Automated tracking

    Links lesions across time points to create longitudinal tracking reports to calculate lesion response automatically.

  • Automated reporting

    Automates therapy response criteria and generates a comprehensive report that can be linked to the patient record in the EMR or Tempus Hub.

Learn more
Next
  • for Providers
  • for life sciences

Next

Identify and close gaps in care.

  • Patient identification

    Identifies patients and contextualizes where they are in the care journey relative to clinical guidelines.

  • Notifications in workflow

    Uses tiered and customized notifications driven by physician preferences.

  • Tracking across the care continuum

    Tracking for patients who need timely management, lists to search for subsets of patients, and dashboards for real-time insights into a hospital’s patient population.

Learn more
Assays
  • for Providers
  • for life sciences

Assays

Our genomic profiling services encompass a broad range of sequencing options, allowing for data-driven patient decisions.

  • xT: 648 gene DNA sequencing panel (includes heme malignancies).
  • xR: Whole-transcriptome RNA sequencing panel (includes heme malignancies).
  • xF/xF+: 105/523 ctDNA sequencing panel.
  • xG/xG+: 52/88 gene panel for hereditary cancers.
  • xE: Whole exome, 19,000+ gene DNA sequencing panel.
Learn more
Algos
  • for Providers
  • for life sciences

Algos

Gain additional insights across multiple cancer types through our algorithmic testing options.

  • HRD: Measures homologous recombination deficiency.
  • TO: Refines diagnosis for cancers with uncertain origins.
  • DPYD: Identifies patients at elevated risk for toxicity to 5 FU and/or capecitabine.
  • UGT1A1: Identifies patients at elevated risk for toxicity to irinotecan, sacituzumab govitecan, and/or belinostat.
  • PurIST℠: Classifies pancreatic ductal adenocarcinomas into one of two subtypes (basal-like or classical).
Learn more

This is data-driven precision medicine

This is the future of healthcare.